Bill Detail

H.R. 1843

Congress: 119

Title

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Summary

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

Sponsor

Rep. Neal Dunn [R-FL-2]

Status

Referred to the House Committee on Energy and Commerce.

Status as of Jun 29, 5:58 AM · synced 14h ago

Introduced

2025-03-05

Open on Congress.gov Congress.gov search Back to directory

Data source mode: cache

Bill Engagement

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively…

Sponsor

Rep. Neal Dunn [R-FL-2]R

Status

Referred to the House Committee on Energy and Commerce.

Cosponsors

1D · 0R

Partisan (D only)

LDA engagement

2 orgs · 2 filings

Top: Chamber of Commerce of the U.s.a.

Introduced

2025-03-05

Lobbyists on the case

2 orgs · 38 lobbyists · 2 filings mention H.R. 1843 (To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.) in LDA disclosures.

Top orgs filing

Chamber of Commerce of the U.s.a.1 filing · 32 lobs
Blue Cross and Blue Shield Association1 filing · 6 lobs

Lobbyists on this bill

Caroline Billman2025 Q1
Chamber of Commerce of the U.s.a.
Neil Bradley2025 Q1
Chamber of Commerce of the U.s.a.
Michael Chirico2025 Q1
Chamber of Commerce of the U.s.a.
Suzanne Clark2025 Q1
Chamber of Commerce of the U.s.a.
Kevin Courtois2025 Q1
Chamber of Commerce of the U.s.a.
Nicholas Crocker2025 Q1
Chamber of Commerce of the U.s.a.
Rodney Davis2025 Q1
Chamber of Commerce of the U.s.a.
Erin Delaney2025 Q1
Chamber of Commerce of the U.s.a.

+ 30 more